Corcept Therapeutics (CORT) Tops Q3 EPS by 5c; Reaffirms
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $79.91 -2.25%
Revenue Growth %: +12.1%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +12.1%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.22, $0.05 better than the analyst estimate of $0.17. Revenue for the quarter came in at $64.4 million versus the consensus estimate of $67.41 million.
GUIDANCE:
Reaffirmed 2018 revenue guidance of $250-270 million
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
- John Wiley & Sons, Inc. (WLY) Tops Q4 EPS by 12c; offers outlook
- Hyperscale Data launches $300M at-the-market stock offering
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
